{
  "trial_id": "NCT01050790",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Diagnosis of multiple myeloma",
      "label": "met"
    },
    {
      "criterion": "Residual measurable disease in partial remission or with stable disease",
      "label": "met"
    },
    {
      "criterion": "Eligible to undergo an autologous stem cell transplant",
      "label": "met"
    },
    {
      "criterion": "Measurable disease defined by quantifiable serum or urinary M protein or free light chains in the presence of a positive immunofixation or bone marrow plasma cells > 5%",
      "label": "met"
    },
    {
      "criterion": "Prior lenalidomide therapy with >= partial response (PR) observed on a prior lenalidomide containing regimen and patients did not progress while receiving lenalidomide",
      "label": "met"
    },
    {
      "criterion": "Minimum period of two weeks elapsed following the prior myeloma therapy; this does not include therapy with bisphosphonates",
      "label": "met"
    },
    {
      "criterion": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
      "label": "met"
    },
    {
      "criterion": "No clinical evidence of uncontrolled viral, fungal, bacterial infection",
      "label": "met"
    },
    {
      "criterion": "Negative serology for human immunodeficiency virus (HIV)",
      "label": "met"
    },
    {
      "criterion": "Serum bilirubin =< 1.5 times upper limit of normal (ULN)",
      "label": "met"
    },
    {
      "criterion": "Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) =< 3x ULN",
      "label": "met"
    },
    {
      "criterion": "Calculated creatinine clearance >= 60ml/min by Cockcroft-Gault formula; creatinine clearance >= 60 ml/min or serum creatinine =< 2.0 mg/dL",
      "label": "met"
    },
    {
      "criterion": "Absolute neutrophil count (ANC) >= 1500/uL",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Known or suspected hypersensitivity to azacitidine or mannitol",
      "label": "triggers"
    },
    {
      "criterion": "Pregnant or breast feeding",
      "label": "triggers"
    }
  ],
  "notes": "Patient has multiple myeloma with residual measurable disease and meets several inclusion criteria. However, she is pregnant which is an exclusion criterion.",
  "_meta": {
    "topic_id": "17",
    "trial_id": "NCT01050790",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}